Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor

Gynecologic Oncology

Volumn 135, Issue 1, 2014, Pages 133-141

  Tierney, Brent J ^a   McCann, Georgia A ^a   Naidu, Shan ^a   Rath, Kellie S ^a   Saini, Uksha ^a   Wanner, Ross ^a   Kuppusamy, Periannan ^b   Suarez, Adrian ^a   Goodfellow, Paul J ^a   Cohn, David E ^a   Selvendiran, Karuppaiyah ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Curcumin analog; Endometrial cancer; HO 3867; STAT3; STAT3 inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; HO 3867; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SERINE; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG; (3,5-BIS((4-FLUOROPHENYL)METHYLIDENE)-1-((1-HYDROXY-2,2,5,5-TETRAMETHYL-2,5-DIHYDRO-1H-PYRROL-3-YL)METHYL)PIPERIDIN-4-ONE); PIPERIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; M PHASE CELL CYCLE CHECKPOINT; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; ENDOMETRIAL NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICE; PIPERIDONES; STAT3 TRANSCRIPTION FACTOR;

EID: 84908018050     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.07.087     Document Type: Article

References (40)

1. S.M. Ueda, D.S. Kapp, M.K. Cheung, J.Y. Shin, K. Osann, and A. Husain Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths Am J Obstet Gynecol 198 218 2008 e1 e6
2. S.B. Dewdney, N.T. Kizer, A.A. Andaya, S.A. Babb, J. Luo, and D.G. Mutch Uterine serous carcinoma: increased familial risk for lynch-associated malignancies Cancer Prev Res (Phila) 5 2012 435 443
3. L.M. Duong, R.J. Wilson, U.A. Ajani, S.D. Singh, and C.R. Eheman Trends in endometrial cancer incidence rates in the United States, 1999-2006 J Womens Health (Larchmt) 20 2011 1157 1163
4. L. Fuso, A. Evangelista, E. Pagano, E. Piovano, S. Perotto, and S. Mazzola Variation in gynecological oncology follow-up practice: attributable to cancer centers or to patient characteristics? A Piedmont Regional Oncology Network Study Tumori 97 2011 551 558
5. K. Armstrong, T.C. Randall, D. Polsky, E. Moye, and J.H. Silber Racial differences in surgeons and hospitals for endometrial cancer treatment Med Care 49 2011 207 214
6. J.N. Bakkum-Gamez, A. Mariani, S.C. Dowdy, A.L. Weaver, M.E. McGree, and J.R. Martin Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy Gynecol Oncol 132 2014 578 584
7. L.J. van der Putten, P. Hoskins, A. Tinker, P. Lim, C. Aquino-Parsons, and J.S. Kwon Population-based treatment and outcomes of stage I uterine serous carcinoma Gynecol Oncol 132 2014 61 64
8. C.E. Humber, J.F. Tierney, R.P. Symonds, M. Collingwood, J. Kirwan, and C. Williams Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Ann Oncol 18 2007 409 420
9. K. Selvendiran, S. Ahmed, A. Dayton, Y. Ravi, M.L. Kuppusamy, and A. Bratasz HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase Mol Cancer Res 8 2010 1188 1197
10. K. Selvendiran, L. Tong, A. Bratasz, M.L. Kuppusamy, S. Ahmed, and Y. Ravi Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts Mol Cancer Ther 9 2010 1169 1179
11. K. Selvendiran, L. Tong, S. Vishwanath, A. Bratasz, N.J. Trigg, and V.K. Kutala EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression J Biol Chem 282 2007 28609 28618
12. K. Selvendiran, S. Ahmed, A. Dayton, M.L. Kuppusamy, B.K. Rivera, and T. Kalai HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition Cancer Biol Ther 12 2011 837 845
13. A. Dayton, K. Selvendiran, M.L. Kuppusamy, B.K. Rivera, S. Meduru, and T. Kalai Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties Cancer Biol Ther 10 2010 1027 1032
14. K. Selvendiran, S. Ahmed, A. Dayton, M.L. Kuppusamy, M. Tazi, and A. Bratasz Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells Free Radic Biol Med 48 2010 1228 1235
15. K.S. Rath, S.K. Naidu, P. Lata, B.H. Hemant, B.K. Rivera, and G.A. McCann HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer Cancer Res 74 2014 2316 2327
16. K.S. Rath, G.A. McCann, D.E. Cohn, B.K. Rivera, P. Kuppusamy, and K. Selvendiran Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs J Ovarian Res 6 2013 35
17. A. Dayton, K. Selvendiran, S. Meduru, M. Khan, M.L. Kuppusamy, and S. Naidu Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867 J Pharmacol Exp Ther 339 2011 350 357
18. T. Kalai, M.L. Kuppusamy, M. Balog, K. Selvendiran, B.K. Rivera, and P. Kuppusamy Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity J Med Chem 54 2011 5414 5421
19. A.K. Fu, W.Y. Fu, A.K. Ng, W.W. Chien, Y.P. Ng, and J.H. Wang Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity Proceedings of the National Academy of Sciences of the United States of America 101 2004 6728 6733
20. S. Courapied, H. Sellier, Trecesson S. de Carne, A. Vigneron, A.C. Bernard, and E. Gamelin The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition J Biol Chem 285 2010 26765 26778
21. K. Selvendiran, H. Koga, T. Ueno, T. Yoshida, M. Maeyama, and T. Torimura Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids Cancer Res 66 2006 4826 4834
22. H. Yu, and R. Jove The STATs of cancer - new molecular targets come of age Nat Rev Cancer 4 2004 97 105
23. X. Zhang, P. Yue, B.D. Page, T. Li, W. Zhao, and A.T. Namanja Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts Proceedings of the National Academy of Sciences of the United States of America 109 2012 9623 9628
24. K.S. Rath, S.K. Naidu, P. Lata, H.K. Bid, B.K. Rivera, and G.A. McCann HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer Cancer Res 74 2014 2316 2327
25. C.L. Chen, F.C. Hsieh, J.C. Lieblein, J. Brown, C. Chan, and J.A. Wallace Stat3 activation in human endometrial and cervical cancers Br J Cancer 96 2007 591 599
26. Z. Wen, and J.E. Darnell Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3 Nucleic Acids Res 25 1997 2062 2067
27. T. Decker, and P. Kovarik Serine phosphorylation of STATs Oncogene 19 2000 2628 2637
28. H.Y. Chan, M.K. Siu, H.J. Zhang, E.S. Wong, H.Y. Ngan, and K.Y. Chan Activated Stat3 expression in gestational trophoblastic disease: correlation with clinicopathological parameters and apoptotic indices Histopathology 53 2008 139 146
29. M. Sakaguchi, M. Oka, T. Iwasaki, Y. Fukami, and C. Nishigori Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells J Invest Dermatol 132 2012 1877 1885
30. T. Mandal, A. Bhowmik, A. Chatterjee, U. Chatterjee, S. Chatterjee, and M.K. Ghosh Reduced phosphorylation of Stat3 at Ser-727 mediated by casein kinase 2 - protein phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells Cell Signal 26 2014 1725 1734
31. P. Yue, and J. Turkson Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18 2009 45 56
32. K. Al Zaid Siddiquee, and J. Turkson STAT3 as a target for inducing apoptosis in solid and hematological tumors Cell Res 18 2008 254 267
33. N. Bansal, V. Yendluri, and R.M. Wenham The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies Cancer Control 16 2009 8 13
34. W. Glienke, E. Hausmann, and L. Bergmann Targeting STAT3 signaling in pancreatic cancer promotes antiapoptotic gene expression Pancreas 40 2011 323 324
35. M. Sen, S. Joyce, M. Panahandeh, C. Li, S.M. Thomas, and J. Maxwell Targeting Stat3 abrogates EGFR inhibitor resistance in cancer Clin Cancer Res 18 2012 4986 4996
36. C.R. Yu, Y.S. Lee, R.M. Mahdi, N. Surendran, and C.E. Egwuagu Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis PLoS One 7 2012 e29742
37. J.Z. Tang, X.J. Kong, A. Banerjee, N. Muniraj, V. Pandey, and M. Steiner STAT3alpha is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone Endocrinology 151 2010 4133 4145
38. F. Ye, H.Z. Chen, X. Xie, D.F. Ye, W.G. Lu, and Z.M. Ding Vascular endothelial growth factor (VEGF) and ovarian carcinoma cell supernatant activate signal transducers and activators of transcription (STATs) via VEGF receptor-2 (KDR) in human hemopoietic progenitor cells Gynecol Oncol 94 2004 125 133
39. H. Chen, D. Ye, X. Xie, B. Chen, and W. Lu VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma Gynecol Oncol 94 2004 630 635
40. Z. Duan, R. Foster, D.A. Bell, J. Mahoney, K. Wolak, and A. Vaidya Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer Clin Cancer Res 12 2006 5055 5063